An operation that targets the nerves connected to the kidney has been found to significantly reduce blood pressure in patients with hypertension, according to the results of a clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust, and supported by the National Institute for Health Research (NIHR).
If the findings are confirmed in more extensive clinical trials, the surgery could offer hope to patients with high blood pressure who do not respond to drugs, and are at increased risk of cardiovascular diseases, including stroke and heart attack.
The international clinical trial, carried out from 2017 to 2018 at St Bartholomew’s Hospital in the UK by the NIHRBarts Biomedical Research Centre, tested a one-hour operation called ‘renal denervation’, which uses ultrasound energy to disrupt the nerves between the kidneys and the brain that carry signals for controlling blood pressure.
Significant reduction in blood pressure
146 patients in the United States, France, Germany, the Netherlands, Belgium and the United Kingdom were randomised to receive either renal denervation or a ‘sham procedure’ – the surgical equivalent of a placebo. Patients also remained off blood pressure medications for two months unless specified blood pressure levels were exceeded.
After two months, the renal denervation group experienced an 8.5 mm Hg reduction in blood pressure, which was a 6.3 mm Hg greater reduction compared with the sham group.
More than 66 per cent of subjects treated with renal denervation demonstrated a 5 mm Hg or greater reduction in blood pressure, compared with 33 per cent in the sham group.
No major adverse events were reported in either group, and the blood pressure lowering effect of renal denervation was consistent across sex and ethnicity.
An alternative to lifelong medications
UK Principal Investigator Dr Melvin Lobo from Queen Mary’s William Harvey Research Institute and Barts Health NHS Trust said: “These results leave us clinicians in no doubt that this ultrasound-based therapy works to improve blood pressure control – at least in the short term. Further larger trials will be needed to confirm the efficacy and safety of the technology, but we hope that they could lead to renal denervation therapy being offered as an alternative to lifelong medications for hypertension.”
The study has limitations including the short follow-up time of two months. This was done for safety reasons to minimise the duration of patients being off antihypertensive medications. Longer follow-up of this trial and additional numbers of treated patients will be necessary to provide greater assurance of safety and to exclude rare adverse events.
Receive an email update when we add a new HYPERTENSION article.
The Latest on: Hypertension
via Google News
The Latest on: Hypertension
- Quantum findings: Firibastat offers NEW-HOPE to control hypertension on November 12, 2018 at 6:38 pm
Quantum Genomics SA made some noise at the Scientific Sessions of the American Heart Association meeting in Chicago with top-line results from its phase IIb NEW-HOPE trial of firibastat (QGC-001), a b... […]
- Hypertension a 'silent killer' that can be treated on November 12, 2018 at 9:52 am
Hypertension a 'silent killer' that can be treated Elevated blood pressure is a major risk factor for myocardial infarction, heart failure, stroke, chronic kidney disease, peripheral artery disease an... […]
- Turmeric Potentially Has Strong Hypertension-fighting Effects on November 12, 2018 at 1:01 am
Turmeric potentially has strong hypertension-fighting effects. This spice contains curcumin, which is a polyphenol that has many healing agents. Some of these healing properties are its ... […]
- Quantum Genomics Announces Excellent Topline Results from Phase 2b NEW-HOPE Study Evaluating Firibastat for Arterial Hypertension on November 11, 2018 at 10:43 pm
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat hypertension and hea... […]
- Investigational urate elevation does not appear to raise hypertension risk on November 11, 2018 at 6:55 pm
A new study may reduce the concern that elevating levels of urate, an approach being investigated to treat several neurodegenerative disorders, could increase the risk of hypertension. A study from a ... […]
- Hypertension Combo Pill Recalled Due to Presence of Probable Carcinogen on November 9, 2018 at 11:00 am
Sandoz announced a voluntary recall of 1 lot of Losartan Potassium and Hydrochlorothiazide Tablets 100mg/25mg due to trace amounts of N-nitrosodiethylamine (NDEA) found in the active pharmaceutical in... […]
- Hypertension in Young Adulthood Linked to CVD Later in Life on November 9, 2018 at 3:19 am
(HealthDay News) -- High blood pressure (BP) in early adulthood is associated with an increased risk for cardiovascular disease (CVD) later in life, according to 2 studies published in the Nov. 6 issu... […]
- Hypertension before 40 linked to early heart disease on November 8, 2018 at 12:40 pm
People who develop high blood pressure before age 40 have a higher risk of heart disease and strokes in middle age, two new studies suggest. One of the studies followed 4,800 young adults in the U.S. ... […]
- Poor oral hygiene can increase your risk of hypertension on November 8, 2018 at 3:03 am
The U.S. Centers for Disease Control estimates about 30 percent of us have high blood pressure, yet fewer than half have it under control with diet, exercise and medications. Poor oral hygiene can ... […]
via Bing News